Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Jetstar to Charge for Overhead Cabin Bags From February 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Miami, FL, March 14, 2018 -- Curative Biosciences, Inc., (OTCBB: CBDX) ("Curative") is pleased to announce that the Financial Industry Regulatory Authority (FINRA) has assigned “CBDX” as the Company's new ticker symbol and it has commenced trading under that symbol today.
For information on Curative and the Company’s portfolio of Hemp CBD oil products please visit www.curativebiosciences.com.
Investor relations information is available by emailing [email protected] or by calling (949) 287-3164.
About Curative Biosciences, Inc.
Curative Biosciences (CBDX), is creating a new category in the health industry by translating advances in science and technology into effective, scientifically sound health products available to people in their everyday lives. We are developing a portfolio of products with compelling compounds found in nature that offer an opportunity for our customers to proactively support their health.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available at the website maintained by the SEC at http://www.sec.gov.
Contact: www.curativebiosciences.com [email protected] (949) 287-3164
